clinical trial · NCT07312136
MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study
Linkoeping University·—·enrolling by invitation·n = 317
MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseCirrhosisAdvanced FibrosisSarcopeniaObesity & OverweightType 2 DiabetesHypertensionOSAS (Obstructive Sleep Apneas Syndrome)
brief summary
The EPSOMIP2 (Evaluating the Prevalence and Severity Of MASLD In Primary care - a Follow-up Study) trial is a longitudinal cohort study of patients with type 2 diabetes recruited from primary health care centers in Östergötland, Sweden. Between 2019-2023, 317 patients were included and underwent rigorous clinical evaluation, vibration controlled transient elastography, biobanking of bloodsamples, and the latest magnetic resonance techniques to liver and body composition. All patients alive will be re-invited to undergo the same evaluation and additional tests.
started
Dec 16, 2025
primary completion
Dec 31, 2031
completion
Dec 31, 2034
last updated
Dec 31, 2025
official title
Evaluating the Prevalence and Severity of MASLD in Primary Care - a Follow-up Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol